


L4

4 L3

=> d l4 1-4 bib abs hitstr


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:354666 CAPLUS
DN 135:137481
TI Synthesis of some new 1,5-benzothiazepines containing 2H-1-benzopyran-2-one heterocycle
AU Prashant, A.; Rao, S. Srinivas; Chowdary, K. S.; Krishnan, V. S. H.
CS Dr. Krishnan's Laboratories, Hyderabad, 072, India
SO Heterocyclic Communications (2001), 7(1), 61-66
CODEN: HCOMEX; ISSN: 0793-0283
PB Freund Publishing House Ltd.
DT Journal
LA English
OS CASREACT 135:137481
GI



AB A facile procedure was developed for the synthesis of 2-aryl/heteryl-4-(2H-1-benzopyran-2-on-8-yl)-2,3-dihydro-1,5-benzothiazepines I [R = H, Me; R1 = Ph, 4-MeOC6H4, 2-thienyl, 3-O2NC6H4, 4-ClC6H4, 4-Me2NC6H4, 4-HO-3-MeOC6H3, 3,4-(MeO)2C6H3, 3-pyridyl; R2 = H, Cl 5a-o] in 50-70% yields by the cyclocondensation reaction of 1-(2H-1-benzopyran-2-one-8-yl)-3-aryl/heteryl-2-propenones with 2-amino-5-R2-thiophenols (R2 = H 4a Cl 4b) in toluene in the presence of trifluoroacetic acid.

IT 79692-52-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and cyclocondensation reaction of, with aminothiophenols)

RN 79692-52-7 CAPLUS
CN 2H-1-Benzopyran-2-one, 7-hydroxy-4-methyl-8-[1-oxo-3-(3-pyridinyl)-2-propenyl]- (9CI) (CA INDEX NAME)





RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS on STM
AN 2001:185740 CAPLUS
DN 134:222628
TI Preparation of 8-(arylpropenoyl)coumarins as antiproliferative agents
IN Bombardelli, Ezio; Valenti, Piero
PA Indena S.p.A., Italy
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

applicant's own

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001017984	A1	20010315	WO 2000-EP8367	20000828
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1212311	A1	20020612	EP 2000-965902	20000828
EP 1212311	B1	20030326		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003508523	T2	20030304	JP 2001-521731	20000828
AT 235480	E	20030415	AT 2000-965902	20000828
US 2002161036	A1	20021031	US 2002-75625	20020215
NO 2002001048	A	20020503	NO 2002-1048	20020301
PRAI GB 2001-999-20908	A	19990903		
WO 2000-EP8367	W	20000828		
OS MARPAT 134:222628				
GI				



AB The title chalcone coumarins (I) [wherein Ar = (un)substituted (hetero)aryl; R = OH, OR₁₀, or OCOR₁₁; R₁₀ = (un)substituted alkyl, alkenyl, or alkynyl; R₁₁ = alkyl, alkenyl, alkynyl, or Ph; R₁ = H or (un)substituted alkyl] were prep'd. as antiproliferative agents for the treatment or prevention of neoplasms, particularly those located in the uterus, ovary, or breast. For example, coupling pyridine-3-carboxaldehyde with 4-methyl-7-(3-methylbut-2-enyloxy)-8-acetylcoumarin in KOH and EtOH afforded II, which reduced the IC₅₀ of paclitaxel from 426 nM to 86 nM against drug-resistant breast cancer cells in a cytotoxicity assay. I may also be useful for the treatment or prevention of menopausal disorders and osteoporosis (no data).


IT 329366-37-2P, 1-[4-Methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl]-3-(pyridine-3-yl)propen-1-one 329366-41-8P, 1-[4-Methyl-7-(2-methylallyloxy)coumarin-8-yl]-3-(pyridine-3-yl)propen-1-one 329366-47-4P, 1-[4-Methyl-7-(allyloxy)coumarin-8-yl]-3-(pyridine-3-yl)propen-1-one

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 8-(arylpropenoyl)coumarin antiproliferative agents by coupling 8-acetylcoumarins with arylaldehydes)


RN 329366-37-2 CAPLUS

CN 2H-1-Benzopyran-2-one, 4-methyl-7-[(3-methyl-2-butenyl)oxy]-8-[1-oxo-3-(3-pyridinyl)-2-propenyl]- (9CI) (CA INDEX NAME)



RN 329366-41-8 CAPLUS

CN 2H-1-Benzopyran-2-one, 4-methyl-7-[(2-methyl-2-propenyl)oxy]-8-[1-oxo-3-(3-pyridinyl)-2-propenyl]- (9CI) (CA INDEX NAME)



AB The title compds. I (R = H, OH; R1 = H, Et), II (R = H, OH), and III (R = H, OH; R2 = H, Me) were prepd. from the corresponding o-hydroxyacetyl coumarin. Thus, 7-hydroxy-8-acetyl-4-Me coumarin was condensed with 3-pyridinecarboxaldehyde and the product cyclized by SeO2 to give I (R = R1 = H).

IT 79692-52-7P 79692-53-8P 79692-54-9P


79692-55-0P 79692-56-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and cyclization of, pyranocoumarin deriv. from)

RN 79692-52-7 CAPLUS

CN 2H-1-Benzopyran-2-one, 7-hydroxy-4-methyl-8-[1-oxo-3-(3-pyridinyl)-2-propenyl]- (9CI) (CA INDEX NAME)



RN 79692-53-8 CAPLUS

CN 2H-1-Benzopyran-2-one, 6-ethyl-7-hydroxy-4-methyl-8-[1-oxo-3-(3-pyridinyl)-2-propenyl]- (9CI) (CA INDEX NAME)


CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2387956	A1	19781117	FR 1977-11871	19770420
	FR 2387956	B1	19810109		
PRAI	FR 1977-11871		19770420		
GI					



I


AB Pyridines I (R = R₁ = H, R₂ = substituted Ph, pyridyl, thienyl, furyl, benzofuranyl, styryl, quinolinyl; X = CO, CHOH, CH₂, C:NOH) were prepd.; they were useful in the treatment of hypoxia, decreased resistance to blood circulation in capillary vessels, increased capillary vessel permeability, and were coronary vasodilators. 4-Formylpyridine in 1% NaOH at room temp. was treated with 2,3,4-(MeO)₃C₆H₂COMe in EtOH to give I [R₁ = bond, R₂ = 2,3,4-(MeO)₃C₆H₂, X = CO] (II). II at 30 mg/kg increased the survival rate of rats at 150 mm Hg 24%.

IT 72512-20-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and treatment of anoxia by)

RN 72512-20-0 CAPLUS

CN 2H-1-Benzopyran-2-one, 7-hydroxy-4-methyl-8-[1-oxo-3-(4-pyridinyl)-2-propenyl]- (9CI) (CA INDEX NAME)



Structures 7



10/075625

=> s wo2000-ep08367/ap
L2 1 WO2000-EP08367/AP
(WO2000-EP8367/AP)

=> d bib abs

L2 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS
AN 2001:185740 CAPLUS
DN 134:222628
TI Preparation of 8-(arylpropenoyl)coumarins as antiproliferative agents
IN Bombardelli, Ezio; Valenti, Piero
PA Indena S.p.A., Italy
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001017984	A1	20010315	WO 2000-EP8367	20000828 <--
	W:				
					AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
	RW:				GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
	EP 1212311	A1	20020612	EP 2000-965902	20000828
	EP 1212311	B1	20030326		
	R:				AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL
	JP 2003508523	T2	20030304	JP 2001-521731	20000828
	US 2002161036	A1	20021031	US 2002-75625	20020215
	NO 2002001048	A	20020503	NO 2002-1048	20020301
PRAI	GB 1999-20908	A	19990903		
	WO 2000-EP8367	W	20000828		
OS	MARPAT 134:222628				
GI					




AB The title chalcone coumarins (I) [wherein Ar = (un)substituted (hetero)aryl; R = OH, OR¹⁰, or OCOR¹¹; R¹⁰ = (un)substituted alkyl, alkenyl, or alkynyl; R¹¹ = alkyl, alkenyl, alkynyl, or Ph; R¹ = H or (un)substituted alkyl] were prep'd. as antiproliferative agents for the treatment or prevention of neoplasms, particularly those located in the uterus, ovary, or breast. For example, coupling pyridine-3-carboxaldehyde with 4-methyl-7-(3-methylbut-2-enyloxy)-8-acetylcoumarin in KOH and EtOH

afforded II, which reduced the IC50 of paclitaxel from 426 nM to 86 nM against drug-resistant breast cancer cells in a cytotoxicity assay. I may also be useful for the treatment or prevention of menopausal disorders and osteoporosis (no data).

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN 2H-1-Benzopyran-2-one, 8-[3-(3-methoxyphenyl)-1-oxo-2-propenyl]-4-methyl-7-(2-propynyloxy)- (9CI)
 MF C23 H18 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):33


L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN 2H-1-Benzopyran-2-one, 4-methyl-8-[1-oxo-3-(3-pyridinyl)-2-propenyl]-7-(2-propenyloxy)- (9CI)
 MF C21 H17 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN 2H-1-Benzopyran-2-one, 4-methyl-7-[(3-methyl-2-butenyl)oxy]-8-[1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]- (9CI)

MF C27 H28 O7




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzaldehyde, 3-methoxy- (9CI)
MF C8 H8 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzaldehyde, 2,6-dichloro- (6CI, 7CI, 8CI, 9CI)
MF C7 H4 Cl2 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2H-1-Benzopyran-2-one, 4-methyl-8-[1-oxo-3-(3-pyridinyl)propyl]-7-(2-propynyloxy)- (9CI)

MF C21 H17 N O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2H-1-Benzopyran-2-one, 4-methyl-8-((1-oxo-3-phenyl-2-propenyl)-7-(2-propenyloxy)- (9CI)
MF C22 H18 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2H-1-Benzopyran-2-one, 4-methyl-7-[(3-methyl-2-butenyl)oxy]-8-((1-oxo-3-phenyl-2-propenyl)oxy)- (9CI)
MF C24 H22 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN 3-Pyridinecarboxaldehyde (9CI)
 MF C6 H5 N O
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN 2H-1-Benzopyran-2-one, 8-[3-(2,6-dichlorophenyl)-1-oxo-2-propenyl]-4-methyl-7-(2-propenyloxy)- (9CI)
 MF C22 H16 Cl2 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN 2H-1-Benzopyran-2-one, 4-methyl-8-(1-oxo-3-phenyl-2-propenyl)-7-(2-propenyloxy)- (9CI)
 MF C22 H16 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN 2H-1-Benzopyran-2-one, 4-methyl-7-[(2-methyl-2-propenyl)oxy]-8-[1-oxo-3-(3,4,5-trimethoxyphenyl)propyl]- (9CI)
 MF C26 H28 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN 2H-1-Benzopyran-2-one, 8-acetyl-4-methyl-7-[(3-methyl-2-butenyl)oxy]- (9CI)
 MF C17 H18 O4






PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Benzaldehyde, 4-fluoro- (9CI)
 MF C7 H5 F O
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN 2H-1-Benzopyran-2-one, 8-acetyl-7-methoxy-3-methyl- (9CI)
 MF C13 H12 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN 2H-1-Benzopyran-2-one, 8-acetyl-4-methyl-7-(2-propynyloxy)- (9CI)
 MF C15 H12 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN 2H-1-Benzopyran-2-one, 8-[3-(3-methoxyphenyl)-1-oxo-2-propenyl]-4-methyl-7-
 [(2-methyl-2-propenyl)oxy] - (9CI)
 MF C24 H22 O5




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN 2H-1-Benzopyran-2-one, 4-methyl-7-[(3-methyl-2-butenyl)oxy]-8-[1-oxo-3-(3-pyridinyl)-2-propenyl] - (9CI)
 MF C23 H21 N O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Benzaldehyde, 4-chloro- (9CI)
 MF C7 H5 Cl O
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN 2H-1-Benzopyran-2-one, 7-methoxy-3-methyl-8-[1-oxo-3-(2-thienyl)-2-propenyl]- (9CI)
 MF C18 H14 O4 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN 2H-1-Benzopyran-2-one, 4-methyl-8-[1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]-7-(2-propynyloxy)- (9CI)
 MF C25 H22 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN 2H-1-Benzopyran-2-one, 4-methyl-7-[(2-methyl-2-propenyl)oxy]-8-(1-oxo-3-phenyl-2-propenyl)- (9CI)
 MF C23 H20 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Benzenepropanoic acid, .beta.-[[[(1,1-dimethylethoxy)carbonyl]amino]-.alpha.-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)- (9CI)
 MF C43 H53 N O14
 CI COM

Absolute stereochemistry.




L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN 2-Pyridinecarboxylic acid (9CI)
 MF C6 H5 N O2
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN 2H-1-Benzopyran-2-one, 8-[3-(4-fluorophenyl)-1-oxo-2-propenyl]-4-methyl-7-(2-propynyloxy) - (9CI)
 MF C22 H15 F O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN 2H-1-Benzopyran-2-one, 4-methyl-3-[1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]-7-(2-propenyloxy) - (9CI)
 MF C25 H24 O7




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN 2H-1-Benzopyran-2-one, 8-acetyl-4-methyl-7-[(2-methyl-2-propenyl)oxy] - (9CI)
 MF C16 H16 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN 2H-1-Benzopyran-2-one, 8-acetyl-4-methyl-7-(2-propenyloxy) - (9CI)
 MF C15 H14 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN 2-Thiophenecarboxaldehyde (7CI, 8CI, 9CI)
 MF C5 H4 O S
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN 2H-1-Benzopyran-2-one, 8-[3-(4-chlorophenyl)-1-oxo-2-propenyl]-4-methyl-7-(2-propenyloxy) - (9CI)
 MF C22 H17 Cl O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN 2H-1-Benzopyran-2-one, 8-[3-(3-methoxyphenyl)-1-oxo-2-propenyl]-4-methyl-7-(2-propenyloxy) - (9CI)
 MF C23 H20 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN 2H-1-Benzopyran-2-one, 4-methyl-7-[(2-methyl-2-propenyl)oxy]-8-[1-oxo-3-(3-pyridinyl)-2-propenyl]- (9CI)
 MF C22 H19 N O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)- (9CI)
 MF C47 H51 N O14
 CI COM

Absolute stereochemistry. Rotation (-).



L3 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Benzaldehyde, 3,4,5-trimethoxy- (6CI, 7CI, 8CI, 9CI)
 MF C10 H12 O4
 CI COM





chain nodes :

11 12 13 14 15 18 19

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

8-18 11-12 11-19 12-13 13-14

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10

exact/norm bonds :

8-18 11-19 13-14

exact bonds :

2-7 3-10 7-8 8-9 9-10 11-12 12-13

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS
12:CLASS 13:CLASS 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS

Element Count :

Node 14: Limited

C,C5

N,N1